(12) **UK Patent Application** (19) **GB** (11) **2 153 780** A

(21) Application No **8503247**

(22) Date of filing **8 Feb 1985**

(30) Priority data

    (31) **579494**   (32) **13 Feb 1984**   (33) **US**

(71) Applicant
Damon Biotech Inc (USA-Delaware),
119 Fourth Avenue, Needham Heights,
Massachusetts 02194, United States of America

(72) Inventors
Wen-Ghih Tsang,
Ann W. Shyr

(74) Agent and/or Address for Service
Graham Watt & Co.,
Riverhead, Sevenoaks, Kent TN13 2BN

(51) INT CL[4]
B01J 13/02

(52) Domestic classification
B8C A

(56) Documents cited
    GB A 2094750   **GB A 2046209**

(58) Field of search
B8C

(54) **Encapsulation of core materials with semi-permeable membranes**

(57) Core materials such as viable cells are encapsulated in consistently semi-permeable membranes by the steps of (a) suspending them in a water soluble polyanionic polymer, (b) dispensing the suspension as drops into an aqueous solution containing polyvalent cations, to form gelled masses, (c) expanding the gelled masses by exposure to an aqueous solution whch removes some of the cations and hydrates the gelled masses, and (d) reacting anionic groups of the polyanionic polymer with cationic groups of a polycationic polymer having a molecular weight greater than 3,000 daltons to form the semi-permeable membranes. The gel expansion step provides continuity and uniformity of the membrane; selection of the polycationic polymer for its charge density and molecular weight governs membrane porosity and the optional deposition of a second membrane reduces porosity, so porosity can be controlled. After membrane formation, the internal gel is preferably reliquefied by a chelating agent, for preference EGTA.

GB 2 153 780 A

SPECIFICATION

Improvements relating to encapsulation of core materials

5 This invention generally relates to improvements in the encapsulation of core materials, including viable   5
cells, within an intracapsular volume defined by a semipermeable membrane. More particularly, the
invention relates to a process for producing large quantities of capsules having uniform membranes with
improved porosity control adapted to promote growth of cells within the capsules.
United States Patent No. 4, 352,883 to Dr. Franklin Lim discloses a basic procedure for encapsulating core
10 materials,including viable cells, within capsules having semipermeable membranes. Viable cells encapsu-   10
lated by that procedure (hereinafter called the "Lim technique") are capable of on-going metabolism,
including mitosis, and secrete materials they would normally secrete in their unencapsulated form. Capsules
made by the Lim technique may be engineered to have membranes which are permeable to molecules
below a particular molecular weight but substantially impermeable to higher molecular weight molecules
15 and to cells. The pores of the membranes are believed to comprise tortuous paths defined by the interstices   15
of the membrane structure. Passage of molecules above a particular molecular weight through the
membrane is hindered by these tortuous path pores, and above a certain higher molecular weight and
corresponding effective molecular dimension, the hindrance is sufficiently great that the membrane is
substantially impermeable to these molecules.
20 Porosity control is an important factor in a number of important uses of such microcapsules. The   20
microcapsule membrane can be used for differential screening, that is, to separate molecules on a molecular
weight basis. For example, United States Patent No. 4,409,331 discloses a method wherein substances
secreted by cells within the capsule may traverse the membrane while other, higher molecular weight
materials are confined within the capsules. Such capsules can simplify greatly collection of substance of
25 interest. Low molecular weight substances of interest can diffuse across the membrane into the   25
extracapsular medium while cell debris and high molecular weight substances and contaminants, e.g.,
pyrogens, are trapped within the intracapsular volume.
The selective screening properties of the capsule membrane also allow the capsules to be used for
cross-strain in vivo growth of hybridomas. The capsule membrane permits cross-strain hybridomas to be
30 grown within a body cavity of an animal whose immune system would normally attack the hybridomas.   30
Astute engineering of membrane permeability properties allows high specificity collection of the secreted
substance.
Effective membrane permeability control also permits the use of implanted capsules containing cells
which secrete an antigen as an immunizing agent. The screening properties of the membrane produce
35 relatively pure antigen as the immunizing agent without the need of a tedious antibody purification   35
procedure and can lead to stimulation of specific antibody production.
Capsules with such membranes can also be used as part of a cell screening procedure. Extracapsular
medium is tested for a substance secreted through the membrane. Contaminants having a molecular weight
greater than the substance are kept within the capsule thereby reducing false positive results.
40 A preferred embodiment of the Lim technique involves the formation of shape-retaining gelled masses   40
which contain the material to be encapsulated, followed by deposition of a membrane on the surface of the
gelled masses. The membrane is formed as relatively high molecular weight materials contact the gel
masses and form ionic cross-links with the gel. Lim discloses that lower molecular weight cross-linking
polymers permeate further into the structure of the gelled masses and result in a reduction of pore size. Lim
45 also discloses that the duration of membrane formation affects pore size. Given a pair of reactants, the   45
longer the cross-linking polymer solution is exposed to the gelled mass, the thicker and less permeable the
membrane.
While the techniques for porosity control and membrane formation disclosed in the Lim U.S. patent No.
4,352,883 can form acceptable membranes, many of the foregoing applications of the capsule technology
50 could be improved if membranes having improved porosity control and better uniformity could be   50
produced. Lim's porosity control techniques do not allow fine tuning of the membrane porosity, but rather
set rough differential filtering limits.
In addition to improved porosity, for commercial purposes it is also important to be able to produce
microcapsules consistently in large numbers having defect-free membranes. In this regard, membranes
55 formed by the Lim technique occasionally have protruding portions of cells or have cells anchored on the   55
capsules. The Lim technique also may produce capsules containing voids which allow cells, the substance of
interest, or unwanted contaminants to escape from the capsule. If some small fraction of the microcapsules
made with a specific purpose in mind have membrane voids, many of the objectives and advantages of the
processes would be frustrated. Accordingly, modifications of the encapsulation processes to promote
60 membrane uniformity and avoid random membrane defects would be advantageous to commercial practice   60
of many of the foregoing processes.
It is therefore an object of this invention to improve porosity control of microcapsule membranes, for
example to promote more uniform membrane formation. Desirably, a process according to the invention
will allow formation of membranes which optimize cellular growth and secretion of substances produced by
65 the cells. A process according to the invention can provide permeable capsule membranes having more   65

precise permeability limits and can permit reproducible engineering of such limits.

According to the present invention, there is provided a process for encapsulating a core material within an intracapsular volume defined by a permeable membrane, said process being adapted to improve membrane uniformity and porosity control and comprising the steps of:

5   A. Gelling a water soluble polyanionic polymer containing the core material with an aqueous solution   5
comprising polyvalent cations to form hydrated, discrete, shape-retaining gelled masses;

B. Expanding the gelled masses with an aqueous solution which removes a portion of the polyvalent cations and further hydrates the gelled masses; and

C. forming a membrane about the expanded gelled masses to form capsules by reaction between anionic
10   groups on the polyanionic polymer and cationic groups on a polycationic polymer having a molecular   10
weight greater than 3,000 daltons.

The invention will now be explained in more detail in the following non-limiting, exemplary description.

The present invention constitutes an improvement on the Lim technique for encapsulating a core material within an intracapsular volume defined by a membrane.

15   As disclosed in the Lim U.S. patent No. 4,352,883 core material is suspended in a solution of a   15
water-soluble polyanionic polymer capabe of being gelled, and the polymer-core material suspension is formed into droplets or other discrete shapes. The droplets then are exposed immediately to a solution of polyvalent cations to produce soft, shape-retaining, hydrated gelled masses. In accordance with this invention the gelled masses, for purposes hereinafter set forth, are next expanded and further hydrated by
20   contact with an aqueous solution which removes a portion of the polyvalent cations, e.g., a saline solution.   20
Thereafter, a membrane is formed about each of the expanded gelled masses by reaction between anionic groups on the polyanionic polymer hydrogel and cationic groups on a polycationic polymer having a molecular weight preferably greater than about 3,000 daltons. The preferred polyanionic polymers are acidic polysaccharides, most preferably alginate salts. Useful polycationic cross-linking polymers include proteins
25   and polypeptides having plural reactive nitrogen-containing cationic groups, e.g., primary amines, polyvinyl   25
amines, aminated polysaccharides, water-soluble salts thereof, and mixtures thereof. The currently preferred polycationic polymer is polylysine. Polyglutamine and polyornithine can also work well. A second membrane layer may be formed about the first by reaction with another polycationic polymer. Any of the cited cationic materials may be used to form the second membrane. The identity of the reactant and the
30   molecular weight of the polycationic polymer or polymers used are selected to determine the porosity   30
characteristics of the capsules. It has also been discovered that the charge density of the polycationic polymers used can have a material effect on porosity control.

The core material may be viable cells, such as geneticaly modified cells, e.g., hybridomas, eukaryotic cells, including animal tissue cells, or prokaryotic cells.

35   The process may also include the step of postcoating the membrane with a water-soluble polyanionic   35
polymer, e.g. an alginate, which reacts with residual cationic sites on the membrane. The gelled masses may be reliquified after membrane formation by reaction with a chelating agent. Ethylene glycol bis- (β-amino ethyl ether)-N,N-tetra-acetic acid and salts thereof (EGTA) are the chelating agents of choice when the capsules are intended for use in growing cells. In this regard, it has been discovered that reliquification with
40   EGTA has the effect of significantly enhancing cellular production of biological materials with the capsules   40
as compared with other chelates such as EDTA or citrate.

Proper selection of reactants and reaction conditions permits formation of membranes of relatively specific permeability. For example, membranes may be engineered to be substantially impermeable to molecules having a molecular weight greater than about 150,000 daltons, and therefore substantially
45   impermeable to all common immunoglobulins. The membranes may be permeable to molecules having a   45
molecular weight up to about 500,000 daltons while precluding passage of higher molecular weight materials. Such capsules permit escape of IgG while retaining IgM. Alternatively, the membranes may be engineered to be permeable to molecules having a weight greater than 500,000 daltons but substantially impermeable to cells.

50   If, for example, a molecular weight cut-off at or below 150,000 daltons is sought, a second membrane may   50
be formed about the capsules with a polycationic polymer having the same, or preferably a higher charge density than a first polycationic polymer, e.g., a polylysine membrane may be post-treated by immersion in a polyornithine or polyvinyl amine solution. If the membrane is to be permeable to molecules of a weight greater than 500,000 daltons, a high molecular weight cross-linking polymer such as a polylysine having a
55   molecular weight greater than 200,000 daltons may be used. Practice of the gel expansion step in accordance   55
with the invention significantly improves capsule membrane uniformity and enhances the efficacy of the porosity control techniques.

As previously noted, the present invention permits improved control of membrane porosity and promotes the formation of more uniform membranes. The invention is based in part on the observation that gelled
60   masses comprising polyanionic polymers, e.g., alginate, can be expanded or contracted by changing the   60
degree of hydration of the polymer. The gel masses contain more than 98% water and are essentially soft, shape-retaining balls having a cross-linked gel lattice. It has been discovered that expanding the gel masses after gelling and before membrane deposition permits one to control better the permeability properties and uniformity of the membranes. Immersing the gelled mass in a solution of monovalent cations, e.g., saline,
65   one or more times will remove a portion of the crosslinking polyvalent cations from the gel and increase the   65

hydration state thereby expanding the gel lattice. Such treatment results in the production of uniformly hydrated gel masses well suited for the subsequent membrane deposition step. In the absence of such treatment, the gel masses vary in size and properties because the first formed masses have been immersed in the gelling solution longer than the last formed masses. Another important observation is that
5 equilibrating the gelled mass with a solution containing polyvalent cations such as a calcium chloride   5
solution will contract the gelled mass. A further phenomenon which has been discovered is that once a membrane has been formed about a gelled mass, immersion of the capsule in a monovalent cation solution will stretch the membrane, increasing the pore size. These phenomena, coupled with the observation that higher charge density cross-linkers tend to reduce ore size, make it possible to control more precisely the
10 membrane permeability. When these observations are coupled with the permeability control techniques   10
disclosed in the aforementioned Lim patent, there is provided to those skilled in the art a set of parameters which enable production of uniform capsules of consistent and more precise permeability properties.
      As disclosed in the Lim patent, the core material is suspended in a solution containing a water-soluble, reversibly gellable polyanionic polymer, preferably sodium alginate, and the polymer-core material
15 suspension is formed into droplets using conventional means, e.g., a jet-head droplet forming aparatus. The   15
jet-head apparatus consists of a housing having an upper air intake nozzle and an elongate hollow body friction fitted into a stopper. A syringe, e.g., a 10 cc syringe, equipped with a stepping pump is mounted atop the housing with a needle, e.g., a 0.01 inch (0.25 mm) I.D. Teflon-coated needle, passing through the length of the housing. The interior of the housing is designed such that the tip of the needle is subjected to a
20 constant laminar airflow which acts as an air knife. In use, the syringe full of the solution containing the   20
material to be encapsulated is mounted atop the housing, and the stepping pump is activated to incrementally force drops of the solution to the tip of the needle. Each drop is "cut-off" by the air stream and falls approximately 2.5-3.5 cm into a gelling solution where it is immediately gelled by absorption of cross-linking ions. The preferred gelling solution is a calcium ion solution, e.g., 1.2% (w/v) calcium chloride.
25 The distance between the tip of the needle and the calcium chloride solution preferably is set to allow the   25
polymer-core material solution to assume the most physically favourable shape, a sphere (maximum volume/surface area). Air within the tube bleeds through an opening in the stopper. The gelled, shape-retaining spheroidal masses or temporary capsules, which preferably are between 50 microns and a few millimeters in diameter, collect in the solution as a separate phase and can be recovered by aspiration.
30   In accordance with the invention the gelled masses are then expanded by one or more separate   30
immersions or washings in a monovalent cation solution, e.g., saline. This immersion removes a portion of the cross-linking calcium ions, and further hydrates the gel. The gelled masses thus expand to provide better coverage of the core material, i.e., the solid phase core material does not protrude through the surface of the gel masses. Solid phase core material which is anchored to the exterior of the gel is removed by the saline
35 wash. Therefore, only core material in the interior of the gel is encapsulated.   35
      The saline washes also promote more uniform capsule membranes by equilibrating the amount of calcium ions cross-linking the alginate lattice of the gel masses. The gel masses are not all formed simultaneously; the droplets which enter the calcium bath early in the gel production cycle spend a longer time in the bath and therefore retain more calcium ions in the gel structure than those droplets which enter
40 late in the cycle. The saline washes remove more calcium ions from the higher density masses (the early   40
gelled droplets) than from the lesser density gel masses thereby equilibrating the calcium content of the gel masses.
      Membranes formed about expanded gel masses are also less prone to rupture due to stresses caused by degelling. It appears that the expanded lattice network may have more resiliency which allows better
45 compensation for degelling stress.   45
      A membrane is then formed about the expanded gelled mass by reaction between cationic groups on the expanded, gelled polyanionic poymer, and anionic groups on a polycationic polymer, e.g. polylysine. The polycationic polymer may have a molecular weight as low as 3,000 daltons, but polylysine of 35,000 daltons or higher molecular weight is preferred. After the membrane is formed about the expanded gelled masses,
50 other steps are utilized to fine tune the porosity of the membrane. For example, a series of washes in a saline   50
solution will expand the pores of the membrane while a series of washes in a calcium chloride solution will contract the pores. A second membrane layer may be formed about the capsules using an additional polycationic poymer, e.g., by exposure to a polyornithine solution or exposure to a higher charged density polymer such as polyvinyl amine. This technique may be used to decrease pore size.
55   As disclosed in the Lim patent, the intracapsular volume preferably is reliquified by immersion of the   55
capsules in a solution of a chelating agent. Chelating agents which have been used with success include ethylene diamine tetra-acetic acid (EDTA), sodium citrate, sodium succinate, and most preferably, ethylene glycol bis- (β -amino ethyl ether) -N,N-tetra acetic acid (EGTA). If sodium citrate is used as the chelating agent, voids may form in the capsule membranes as the membranes take an irregular shape in response to
60 the pressure of citrate. The membrane returns to its original shape as the citrate approaches equilibrium with   60
the intracapsular volume, but if the core material is a living cell sensitive to citrate, cell growth or the cells ability to produce biological materials may be impaired. In contrast, immersion of a capsule in EGTA solution appears to cause the membrane to fold inwardly and remain in this altered configuration until the EGTA is removed. As described in Example 4, *infra*, it appears that cells grow better and are metabolically more
65 active in capsules treated with EGTA as opposed to citrate or other chelating agents tested.   65

As disclosed in the Lim patent, post-coating the capsules with a solution of a polyanionic polymer, e.g., sodium alginate, substantially removes the tendency for the capsules to clump. The anionic polymer reacts with residual cationic sites on the membrane causing negative surface polarity. As is known in the prior art, negative surfaces may inhibit growth and attachment of cells. Such growth can hinder intracapsular cell

5 growth or adversely affect permeability. Additionally, immersing the capsule in a neutralizing agent such as 2-N-cyclohexylamino ethane sulfonic acid (CHES) or other zwitterion buffer may reduce the reactivity of and improve the capsule membrane.

The following non-limiting examples will further illustrate the processes of the invention and their advantages.

10
Example 1

The following procedure may be used to produce capsules substantially impermeable to molecules having a molecular weight greater than about 150,000 daltons. A hybridoma, which produces IgG (molecular weight about 160,000 daltons), was used in this experiment.

15 Approximately 2.1 liters of a suspension containing about 2.2×10^6 cells/ml in 1% (w/v) sodium alginate (NaG-Kelco LV) was transferred to a jet-head apparatus, as previously described, and droplets were formed by forcing the suspension through sixteen 22 gauge needles at a rate of approximately 50 ml/minute. The droplets fell approximately 3 cm into 5 liters of a 1.2% (w/v) calcium chloride solution, forming gelled masses which were collected by aspiration and transferred to a 10 liter flask containing approximately 5 liters of

20 isotonic saline for gel expansion. The saline was removed and replenished twice. In total, the saline expansion took approximately 11 minutes. Next, a membrane was formed about the gelled masses by contact with 5 liters of a 750 mg/l poly-L-lysine (Sigma Chemical Company, 65,000 dalton molecular weight) in isotonic saline solution. After 12 minutes of reaction, the resulting capsules were washed for 10 minutes with 5 liters of a 1.4 g/l solution of CHES buffer (Sigma) containing 0.2% (w/v) calcium chloride in saline. The

25 capsules were washed for approximately 8 minutes with 5 liters of 0.3% (w/v) calcium chloride in saline, a second membrane was formed about the capsules by a 10 minute reaction in 5 liters of a 150 mg/l polyvinyl amine (Polyscience, 50,000-150,000 dalton molecular weight) in saline. The capsules were washed again with two 5 liters volumes of isotonic saline, over 7 minutes and post-coated with a 7 minute immersion in 5 liters of 5×10^{-2}% (w/v) NaG in saline solution. The capsules were washed for an additional 4 minutes in 5

30 liters of saline then the intracapsular volumes were reliquified by two immersions in 5 liter volumes of 55 mM sodium citrate in saline solution, the first for 10 minutes and the second for 6 minutes. As disclosed in Example 4, infra, replacing the sodium citrate solution with an EGTA solution would improve antibody yield. The capsules were washed twice in 5 liters of saline and washed once for 4 minutes in RPMI medium. The capsules were then allowed to grow in the growth medium, RPMI plus 10% fetal calf serum. IgG collects

35 within the capsules and only trace quantities can be detected in the extracapsular medium. Capsules prepared according to this procedure are accordingly substantially impermeable to IgG but permit free tranverse of required nutrients thereby permitting cell growth and antibody production within the intracapsular volume.

40
Example 2

This example illustrates a procedure for forming capsules which are permeable to IgG (molecular weight about 160,000 daltons) but substantially impermeable to IgM (molecular weight about 900,000 daltons). The cell used was a human-human hybridoma 77 from the National Institute of Health which produces and secretes human IgM.

45 Four hundred ml of a solution containing 1×10^6 cells/ml in 1% NaG (w/v) were formed into droplets using a bunch of eight 22 gauge needles in a jet-head apparatus as previously described. The feed rate was approximately 30 ml/minute and the distance from the needle tip to the gelling solution, 1 liter of 1.2% (w/v) calcium chloride, was about 3 cm. The gelled masses were washed three times with 1 liter volumes of isotonic saline over an 8 minute period and immersed for 10 minutes in 1 liter of 750 mg/ml of poly-L-lysine

50 (Sigma, 65,000 dalton molecular weight) to form a permanent membrane. The resulting capsules were washed for 5 minutes in 1 liter of 1.4 g/l CHES containing 0.2% (w/v) calcium chloride in saline, then washed for 5 mintues with 1 liter of 0.3% (w/v) calcium chloride in saline solution. Capsules were expanded for 4 minutes with 1 liter of saline then post-coated for 7 minutes in 1 liter of 3×10^{-2}% (w/v) NaG in saline. The post-coated capsules were washed for 5 minutes in a 1 liter of saline solution then the intracapsular volumes

55 were reliquified by two 6 minute immersions in 1 liter of a 55 mM sodium citrate in saline solution. The citrate was removed by two washes with saline, 1 liter each, and the resulting capsules were washed for 5 minutes in RPMI medium. The capsules were then suspended in one liter of medium (RPMI plus 20% fetal calf serum and antibiotics), and the cells therein were allowed to grow. The extracapsular medium was sampled. By assay it was determined that the extracapsular medium contained no IgM, showing that the

60 capsules were substantially impermeable to molecules having 900,000 dalton molecular weight.

Example 3

This example discloses a procedure for forming capsules which are permeable to IgM (molecular weight about 9000,000 daltons) but impermeable to cells. Two hundred ml of a 1% (w/v) solution of NaG (Kelco LV)

65 and the hybridoma cells of Example 2 were formed into droplets through five 26 gauge needles in a jet head

apparatus as previously described. The resulting droplets fell approximately 2.5 cm into the gelling solution, 1 liter of 1.2% (w/v) calcium chloride, at a rate of 9.5 ml/m. The resulting gelled masses were expanded by three immersions in 0.5 liter volumes of saline and a permanent membrane was formed by a 10 minute reaction with 0.5 liter of one g/l poly-L-lysine (Sigma, average molecular weight about 260,000 daltons). The
5 capsules were washed for five minutes in 0.5 liters of 1.4 g/l CHES-saline solution containing 0.6% (w/v) calcium chloride and for an additional five minutes in 0.5 liters of 0.8% (w/v) calcium chloride in saline solution. The capsules were then washed once in 0.5 liters of saline and post-coated with 0.5 liters of 0.03% (w/v) NaG. The post-coated capsules were washed for 5 minutes in 0.5 liters of saline and the intracapsular volume was reliquified by two 5 minute washes, 0.5 liters each, of 55 mM sodium citrate. The capsules were
10 washed once in saline, once in basal medium, and suspended in basal medium containing 20% fetal calf serum plus antibiotics. IgM was found to traverse the capsular membrane but cells were retained showing that the membrane is permeable to molecules of at least 900,000 molecular weight but is impermeable to cells.

15 *Example 4*

This example demonstrates that the metabolic activity of encapsulated cells can be greatly enhanced by proper selection of the chelating agent used to reliquify the intracapsular volume. Four different chelating agents were tested: EDTA, EGTA, sodium citrate and sodium succinate, using encapsulated IgG producing Li8 hybridoma as a test system. The capsules were made following the procedure set forth in Example 1
20 except the sodium citrate of Example 1 was replaced with the concentrations of the chelating agents listed below.

TABLE 1

Degelling Reagent	Conc. (mM)	Total Cell # at (day)	Days of Culture	end Culture μg/ml (day)
EDTA	55	1.0×10^6 (6)	6	0
EGTA	55	4.3×10^7(17)	27	1026
Citrate	55	2.3×10^7(16)	19	366
EGTA	55	3.5×10^7(16)	19	741
Succinate	55	2.3×10^7(16)	19	—
EGTA	55	3.6×10^7(19)	21	939
EGTA	36	4.1×10^7(19)	21	892
EGTA	28	3.7×10^7(19)	21	734
EGTA	28	9.3×10^7(27)	27	659
		5.3×10^7(20)		578(20)
EGTA	28	6.0×10^7(27)	27	693
		4.1×10^7(20)		590(20)
EGTA	14	7.3×10^7(27)	27	887
		5.4×10^7(20)		780(20)

Table 1 illustrates that the EGTA is the best chelating agent for cell growth and results in improved antibody production as compared with citrate approximately by a factor of 2.

The remaining entries in Table 1 illustrate experiments to determine the optimum EGTA concentration for
50 degelling and antibody production. As is evident from the data, it appears that 36 mM and 55 mM concentrations of EGTA are approximately equivalent in promoting antibody production while lower concentrations of EGTA yield lower antibody concentrations despite having roughly identical cell growth.

Example 5
55 This example illustrates the effect of using multiple saline washes to expand the gel masses prior to membrane formation. The same capsule formation procedure and hybridoma as described in Example 1 was used except the number of saline washes conducted before membrane formation was modified. After capsule formation, the encapsulated hybridomas were grown for 20 days in the culture medium and the total cell count and intracapsular antibody concentration was measured. Table 1 gives the results of this
60 experiment.

TABLE 1

RUN #	Number of Saline Washes	Days in Culture	Total Cell #	Intracapsular Ab Conc. μg/ml
441A	None	20	4.3×10^7	360
441B	1	20	5.0×10^7	560
441C	2	20	7.2×10^7	702
441C	3	20	6.5×10^7	717

As may be seen from the data compiled in Table 1, using two or three saline washes produced the highest cell count and the highest intracapsular antibody concentration. More specifically, after three premembrane formation washes with saline, the culture grew about 50% more cells and produced almost double the intracapsular antibody concentration as the culture which was not washed in saline. This experiment illustrates that premembrane formation washing with saline improves the capsules so that the encapsulated hybridomas are healthier and produce more antibody.

From the foregoing it will be apparent that in view of this disclosure those skilled in the art will be able to design specific encapsulation techniques which will consistently produce uniform capsule membranes having permeability properties tailored for specific applications using empirical procedures. Thus, by astute exploitation of the encapsulation parameters disclosed herein, the artisan can produce capsules which will permit free transport through the membrane of molecules up to a selected molecular weight, permit hindered transport of molecules in a range above that weight, and preclude traverse of molecules of a molecular weight and related effective molecular dimensions above the range. Once the procedure has been developed, it can be practiced to manufacture as many capsules as desired for the purpose intended.

In designing a procedure to produce capsules of a specific permeability behaviour, the following should be used as general guiding principles. The gel expansion step improves capsule membrane uniformity and increases the effectiveness of the porosity control techniques. Increases in the charge density of the polycationic membrane forming polymers generally produce smaller pores. Increases in the molecular weight of the polycationic polymer generally produce larger pores and thinner membranes. Increases in the duration of the exposure of the polycationic polymer to the gel masses produce a thicker, less permeable membrane. The deposition of a second polycationic polymer over the first reduces the pore size. Expansion of the gel by hydration after membrane formation increases the porosity and contraction decreases porosity. When designing capsules for implantation, a post-coating with a polyanionic polymer is desirable and physiologically incompatible membrane forming materials which cause inflamation or fibroblastic overgrowth should be avoided. When designing capsules for culturing cells, reliquification is desirable and is best conducted using EGTA.

Accordingly, the invention may be embodied in other specific forms without departing from the scope thereof and all of the foregoing embodiments should be considered illustrative.

CLAIMS

1. A process for encapsulating a core material within an intracapsular volume defined by a permeable membrane, said process being adapted to improve membrane uniformity and porosity control and comprising the steps of:
   A. Gelling a water soluble polyanionic polymer containing the core material with an aqueous solution comprising polyvalent cations to form hydrated, discrete, shape-retaining gelled masses;
   B. Expanding the gelled mases with an aqueous solution which removes a portion of the polyvalent cations and further hydrates the gelled masses; and
   C. forming a membrane about the expanded gelled masses to form capsules by reaction between anionic groups on the polyanionic polymer and cationic groups on a polycationic polymer having a molecular weight greater than 3,000 daltons.

2. The process according to claim 1 comprising the additional step of post-coating the membrane formed in step C with a water-soluble polyanionic polymer by reaction with residual cationic sites on the membrane.

3. The process according to claim 1 or claim 2, comprising the additional step of reliquifying the gelled masses after membrane formation.

4. The process according to claim 3, wherein the reliquifying step comprises exposing the capsules to a chelating agent.

5. The process according to claim 4, wherein the chelating agent comprises ethylene glycol bis- (β-amino ethyl ether) – N, N-tetra-acetic acid or a salt thereof.

6. The process according to claim 1 or claim 2, comprising the additional step of forming a second membrane layer about the membrane formed in step C by reaction with a second polycationic polymer.

7.   The process according to claim 6, comprising the additional step of post-coating the membrane with a water-soluble polyanionic polymer by reaction with residual cationic sites on at least one of said polycationic polymers.

8.   The process according to claim 6 or claim 7, comprising the additional step of reliquifying the gelled
5 masses after membrane formation.   5

9.   The process according to claim 8, wherein the reliquifying step comprises exposing said capsules to a chelating agent.

10.   The process of claim 9 wherein said chelating agent is ethylene glycol bis- (β -amino ethyl ether) N, N-tetra-acetic acid or a salt thereof.

10   11.   The process according to any of claims 1 to 10, wherein the polyanionic polymer is selected from a   10
group consisting of acidic polysaccharides.

12.   The process according to claim 11, wherein the acidic polysaccharide is an alginate salt.

13.   The process according to any of claims 1 to 12, wherein the polycationic polymer is selected from proteins comprising plural reactive nitrogen-containing cationic groups, polypeptides comprising plural
15 reactive nitrogen-containing cationic goups, polyvinyl amines, aminated polysaccharides, salts thereof, and   15
mixtures thereof.

14.   The process according to claim 13, wherein the polycationic polymer is selected from polylysine, polyglutamine, and polyornithine.

15.   The process according to claim 6 or any claim dependent directly or indirectly on claim 6, wherein the
20 second polycationic polymer is selected from proteins comprising plural reactive nitrogen-containing   20
cationic groups, polypeptides comprising plural reactive nitrogen-containing cationic goups, polyvinyl amines, polyethylene amines, aminated polysaccharides, mixtures thereof, and salts thereof.

16.   The process according to claim 15 wherein the second polycationic polymer is selected from polylysine, polyglutamine, and polyornithine.

25   17.   The process according to any preceding claim, wherein the aqueous solution of step B comprises   25
monovalent cations.

18.   The process according to claim 17, wherein the aqueous solution is saline.